节点文献

猪胸膜肺炎放线杆菌血清1型RTX毒素I的N-端表达多肽具有良好的免疫原性

Study on Immunogenicity of the N-terminal Polypeptide of RTX Toxin I of Actinobacillus pleuropneumoniae

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 梅岭周锐卢海松贝为成刘维红林荔雯洪文洲陈焕春

【Author】 MEI Ling1, ZHOU Rui 1,2*, LU Hai-Song1, BEI Wei-Cheng2, LIU Wei-Hong1, LIN Li-Wen1, HONG Wen-Zhou2 and CHEN Huan-Chun 1,21 Division of Animal Infectious Disease in the State Key Laboratory of Agricultural Microbiology, Wuhan 430070, China2 College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China

【机构】 农业微生物学国家重点实验室动物病原微生物分室华中农业大学动物医学院农业微生物学国家重点实验室动物病原微生物分室 武汉430070武汉430070华中农业大学动物医学院武汉430070

【摘要】 ApxI外毒素是猪胸膜肺炎放线杆菌(APP)最重要的毒力因子,为了研究其N端多肽的免疫原性,分别将apxIA基因的全长编码区(apxIA,3146bp)及其5′端1140bp的片段(apxIA5)克隆到原核表达载体pET28a,经IPTG诱导后在大肠杆菌中实现了表达,表达产物ApxIA和ApxIAN均以包涵体的形式存在,Westernblot检测证实两种表达产物均具有免疫反应性。将纯化的重组蛋白(rApxIA和rApxIAN)和提取的天然毒素ApxI(nApxI)分别经腹腔免疫BALBc小鼠,于免疫前、免疫2周和4周后分别检测了ELISA抗体和毒素中和抗体水平,结果表明,rApxIAN免疫组的ELISA抗体显著低于rApxIA免疫组和nApxI免疫组,但rApxIAN免疫组血清中和试验中测定的溶血素单位与rApxIA及天然nApxI免疫组没有显著差异。第二次免疫2周后,用1个LD50的APP血清1型J101株和2型标准菌株攻击试验动物,rApxIAN免疫组对血清1型和2型菌株的保护率分别为80%和100%。

【Abstract】 ApxI is one of the most important virulence factors of Actinobacillus pleuropneumoniae (APP). To study the immunogenicity of the ApxI, the complete coding sequence (3146bp) and its 5′-terminal 1140 bp fragment of the apxIA gene were separately cloned into the prokaryotic expression vector pET-28a, and expressed in the E. coli BL21 (DE3) with induction by IPTG. The expression products, rApxIA and rApxIAN, were present in a form of inclusion bodies and showed the same immunological reactivity as natural ApxI (nApxI) in Western-blot analysis. BALB/c mice were intraperitoneally immunized with the rApxIA, rApxIAN and nApxI respectively. The serum antibody levels of the rApxIAN immunized mice were significantly lower than those immunized with rApxIA or nApxI in an ApxI-specific ELISA, but serum neutralization test demonstrated that immunized mice with rApxIAN, rApxIA and nApxI could generate similar levels of antibodies neutralizing the hemolytic activity of the natural ApxI. The rApxIAN was able to elicite 80% protection rate against APP serovar 1 and 100% against serovar 2 when challenged at a dose of one LD50 after 2 weeks of boost immunization.

【基金】 教育部新世纪优秀人才支持计划(NCET040740);国家自然科学基金(No.30200011)~~
  • 【文献出处】 生物工程学报 ,Chinese Journal of Biotechnology , 编辑部邮箱 ,2006年01期
  • 【分类号】S852.61
  • 【被引频次】7
  • 【下载频次】185
节点文献中: 

本文链接的文献网络图示:

本文的引文网络